PREDI-ENDO
PREDI-ENDO is a UK study within the EU-funded PREDI-LYNCH programme. It is testing whether less invasive samples, including urine, vaginal swabs, Ellele samples and blood tests, can help detect womb cancer earlier in people with Lynch syndrome.
Why this study matters
Lynch syndrome is an inherited condition that increases the risk of several cancers, including womb cancer.
For people with a uterus, womb cancer is one of the most important cancer risks linked with Lynch syndrome.
Current monitoring methods, such as endometrial biopsy or transvaginal ultrasound, can be uncomfortable, are not always widely used, and the evidence for routine screening is still evolving.
PREDI-ENDO is exploring whether simpler, less invasive samples — including samples taken at home — can provide useful information about cancer risk and early detection.
Key question: Can less invasive samples help detect womb cancer earlier and make surveillance more acceptable?
About the study
PREDI-ENDO is the gynaecological arm of PREDI-LYNCH, a European research programme developing new approaches for earlier cancer detection in people with Lynch syndrome.
The study focuses on womb cancer (endometrial cancer) and compares different types of samples and tests.
Some samples may be collected at home, while others are collected in clinic:
- Urine samples (at home)
- Vaginal swabs (at home)
- Blood samples (in clinic)
- Ellele vaginal samples (in clinic)
The study may also include information from routine care, such as ultrasound, biopsy or hysteroscopy, where these are clinically indicated.
The goal is to understand whether these approaches could support — or in future reduce the need for — more invasive monitoring.
Who can take part?
The study team will confirm eligibility at participating NHS sites. In general, the study may be relevant for:
- Adults aged 18 or over
- People who have a uterus
- People with confirmed Lynch syndrome
- Some people with mismatch repair deficient endometrial cancer
- People able to give informed consent
You may not be able to take part if you:
- Are pregnant at enrolment
- Have an active urogenital cancer
- Are unable to provide a vaginal sample
- Are taking part in certain other clinical trials
This is a general guide only. The study team will confirm eligibility.
What taking part involves
- Find out about the study
You will receive information and have time to ask questions. - Join the study
If you choose to take part, you will give consent. - Provide samples
Some samples are taken at home (urine and vaginal swab), and some in clinic (blood and Ellele samples). - Complete questionnaires
You may be asked about symptoms, quality of life, and how acceptable you found the tests. - Follow-up
Participants may be followed for up to 24 months.
Important to know
- Taking part is voluntary
- You can withdraw at any time
- Your usual care will continue
- The study aims to improve future care
How can I take part?
PREDI-ENDO is not yet open to recruitment.
The study is planned to open in the UK in Q4 2026, subject to approvals and site readiness.
When recruitment opens, eligible people are expected to be approached through NHS clinical teams.
If you think this study may be relevant to you, speak to your clinical team or check back here for updates.
Frequently asked questions
Does this replace my usual care?
No. This is a research study. Your routine care and treatment remain the responsibility of your clinical team.
Will I benefit directly?
You may not benefit directly. The main benefit is contributing to research that could improve future cancer detection and monitoring.
Will I receive my results?
The tests are investigational. Relevant findings may be shared with your clinical care team for follow-up where appropriate.
Do I have to take part?
No. Participation is voluntary, and choosing not to take part will not affect your care.
Can I withdraw?
Yes. You can leave the study at any time.
How is my data handled?
Your data will be stored securely and used in a coded form where possible to protect your identity.
Can I take part if I do not want invasive surveillance?
Some participants may take part in a minimal-contact group with follow-up through medical records or registry data.